Vorasidenib

Vorasidenib (AG-881) is an orally available, brain penetrant second-generation dual mutant isocitrate dehydrogenases 1 and 2 (mIDH1/2) inhibitor. Vorasidenib (AG-881) exhibits nanomolar inhibition of (D) -2-hydroxyglutarate (D-2-HG), and the IC50 ranges of 0.04~22 nM against IDH1 R132C, IDH1 R132G, IDH1 R132H and IDH1 R132S and 7~14 nM against IDH2 R140Q and 130 nM against IDH2 R172K. Vorasidenib can be used for the study of grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1/2 mutation[1][2].

Product Specifications

CAS Number

[1644545-52-7]

Product Name Alternative

AG-881

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Isocitrate Dehydrogenase (IDH)

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Vorasidenib.html

Concentration

10mM

Purity

99.87

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

C[C@@H](NC1=NC(C2=NC(Cl)=CC=C2)=NC(N[C@H](C)C(F)(F)F)=N1)C(F)(F)F

Molecular Formula

C14H13ClF6N6

Molecular Weight

414.74

Precautions

H302, H315, H319, H335

References & Citations

[1]Fujii T, et al. Targeting isocitrate dehydrogenase (IDH) in cancer. Discov Med. 2016 May;21 (117) :373-80.|[2]Ma T, et al. Inhibitors of Mutant Isocitrate Dehydrogenases 1 and 2 (mIDH1/2) : An Update and Perspective. J Med Chem. 2018 Oct 25;61 (20) :8981-9003.